

**Osprey Pharmaceuticals USA receives CTA approval from Health Canada for its first Leukocyte Population Modulator.**

On January 8th 2009, Health Canada approved the Company's Clinical Trial Application (CTA) for its first Leukocyte Population Modulator (LPM). The lead candidate, OPL-CCL2-LPM targeting the CCR2 receptor, is now projected to enter a Phase Ib clinical trial for the treatment of IgA nephropathy in early 2009.

**About Osprey Pharmaceuticals USA**

Osprey Pharmaceuticals USA is based in San Francisco, USA, and focuses on the development of novel protein therapeutics for the treatment of inflammatory and immune diseases. The company is advancing a pipeline of proprietary fusion protein therapeutics known as Leukocyte Population Modulators (LPMs) that are designed to selectively target and neutralize chemokine-activated leukocytes underlying a variety of inflammatory and immune diseases.

For more information visit [www.ospreypharma.com](http://www.ospreypharma.com).